SG11202010596PA - Soluble complement receptor type 1 variants and uses thereof - Google Patents
Soluble complement receptor type 1 variants and uses thereofInfo
- Publication number
- SG11202010596PA SG11202010596PA SG11202010596PA SG11202010596PA SG11202010596PA SG 11202010596P A SG11202010596P A SG 11202010596PA SG 11202010596P A SG11202010596P A SG 11202010596PA SG 11202010596P A SG11202010596P A SG 11202010596PA SG 11202010596P A SG11202010596P A SG 11202010596PA
- Authority
- SG
- Singapore
- Prior art keywords
- variants
- receptor type
- complement receptor
- soluble complement
- soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018901703A AU2018901703A0 (en) | 2018-05-16 | Soluble complement receptor Type I variants and uses thereof | |
PCT/AU2019/050456 WO2019218009A1 (en) | 2018-05-16 | 2019-05-15 | Soluble complement receptor type 1 variants and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010596PA true SG11202010596PA (en) | 2020-11-27 |
Family
ID=68539129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010596PA SG11202010596PA (en) | 2018-05-16 | 2019-05-15 | Soluble complement receptor type 1 variants and uses thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210238238A1 (en) |
EP (1) | EP3793586B1 (en) |
JP (1) | JP2021524846A (en) |
KR (1) | KR20210013091A (en) |
CN (1) | CN112118859A (en) |
AU (1) | AU2019268410A1 (en) |
BR (1) | BR112020022405A2 (en) |
CA (1) | CA3100071A1 (en) |
SG (1) | SG11202010596PA (en) |
WO (1) | WO2019218009A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104302177B (en) * | 2012-05-17 | 2019-05-28 | 延伸生物科学股份有限公司 | Carrier for improved drug delivery |
CN112898437B (en) * | 2021-03-24 | 2024-02-02 | 思格(苏州)生物科技有限公司 | New coronavirus antigen and preparation method and application thereof |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981481A (en) * | 1974-12-06 | 1999-11-09 | The Johns Hopkins University | Human C3b/C4b receptor (CR1) |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
ATE135370T1 (en) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
CA2288429C (en) | 1991-03-15 | 2006-04-25 | Synergen, Inc. | Pegylation of polypeptides |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
EP0649468B1 (en) | 1992-06-24 | 2000-03-15 | AdProTech plc | Soluble cr1 derivatives |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | Target binding polypeptide. |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
CA2162600C (en) | 1993-05-17 | 2000-07-11 | Chrales W. Rittershaus | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
JP4309051B2 (en) | 1998-03-02 | 2009-08-05 | マサチューセッツ インスティテュート オブ テクノロジー | Polyzinc finger protein with improved linker |
JP2002534959A (en) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | Methods for modifying immunogenic proteins |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1658095A4 (en) | 2003-06-02 | 2006-06-14 | Alexion Pharma Inc | De-immunized anti-cd3 antibody |
CA2537273A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
DK2325207T3 (en) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc variants with altered binding to FcRn |
CA2619244A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
JP2009521213A (en) * | 2005-12-24 | 2009-06-04 | ティーガスク デイリー プロダクツ リサーチ センター | Process for producing trans-10, cis-12octadecadienoic acid |
US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
MX2012004793A (en) | 2009-10-30 | 2012-07-20 | Novozymes Biopharma Dk As | Albumin variants. |
AU2011218294A1 (en) | 2010-02-16 | 2012-08-30 | Medimmune, Llc | HSA-related compositions and methods of use |
KR20130080443A (en) * | 2010-05-14 | 2013-07-12 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Improved complement receptor 2(cr2) targeting groups |
NZ603399A (en) * | 2010-05-17 | 2014-09-26 | Cebix Inc | Pegylated c-peptide |
CA2815237C (en) * | 2010-10-27 | 2018-10-09 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type i (scr1) |
WO2012112188A1 (en) | 2011-02-15 | 2012-08-23 | Medimmune, Llc | Hsa-related compositions and methods of use |
WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
AU2012318288B2 (en) * | 2011-12-01 | 2015-09-17 | Ap Biosciences, Inc. | Protein inhibitors to complement and VEGF pathways and methods of use thereof |
CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
US10208102B2 (en) | 2013-11-01 | 2019-02-19 | University Of Oslo | Albumin variants and uses thereof |
MA39819A (en) * | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Methods and compositions for immunomodulation |
EP3697812A4 (en) | 2017-10-18 | 2021-09-22 | CSL Limited | Human serum albumin variants and uses thereof |
-
2019
- 2019-05-15 KR KR1020207036132A patent/KR20210013091A/en unknown
- 2019-05-15 SG SG11202010596PA patent/SG11202010596PA/en unknown
- 2019-05-15 BR BR112020022405-7A patent/BR112020022405A2/en unknown
- 2019-05-15 CN CN201980032779.6A patent/CN112118859A/en active Pending
- 2019-05-15 WO PCT/AU2019/050456 patent/WO2019218009A1/en unknown
- 2019-05-15 US US17/053,981 patent/US20210238238A1/en active Pending
- 2019-05-15 JP JP2020564231A patent/JP2021524846A/en active Pending
- 2019-05-15 EP EP19803150.2A patent/EP3793586B1/en active Active
- 2019-05-15 CA CA3100071A patent/CA3100071A1/en active Pending
- 2019-05-15 AU AU2019268410A patent/AU2019268410A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019268410A1 (en) | 2020-12-17 |
WO2019218009A1 (en) | 2019-11-21 |
CA3100071A1 (en) | 2019-11-21 |
KR20210013091A (en) | 2021-02-03 |
EP3793586A4 (en) | 2022-04-06 |
EP3793586A1 (en) | 2021-03-24 |
EP3793586B1 (en) | 2024-04-10 |
JP2021524846A (en) | 2021-09-16 |
CN112118859A (en) | 2020-12-22 |
BR112020022405A2 (en) | 2021-04-13 |
US20210238238A1 (en) | 2021-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202010596PA (en) | Soluble complement receptor type 1 variants and uses thereof | |
AU2018901703A0 (en) | Soluble complement receptor Type I variants and uses thereof | |
GB201815169D0 (en) | Concept 186 | |
GB201814002D0 (en) | Concept 181 | |
GB201812055D0 (en) | Concept 180 | |
GB201811671D0 (en) | Concept 179 | |
GB201811276D0 (en) | Concept 178 | |
GB201810892D0 (en) | Concept 172 | |
GB201810890D0 (en) | Concept 175 | |
GB201810891D0 (en) | Concept 176 | |
GB201809927D0 (en) | Concept 178 | |
GB201809434D0 (en) | Concept 174 | |
GB201808988D0 (en) | Concept 171 | |
GB201808985D0 (en) | Concept 173 | |
GB201808987D0 (en) | Concept 172 | |
GB201807532D0 (en) | Concept 170 | |
GB201807081D0 (en) | Concept 23 | |
GB201807134D0 (en) | Concept 35 | |
GB201807117D0 (en) | Concept 32 | |
GB201807121D0 (en) | Concept 33 | |
GB201807094D0 (en) | Concept 22 | |
GB201807079D0 (en) | Concept 168 | |
GB201807080D0 (en) | Concept 54 | |
GB201807124D0 (en) | Concept 36 | |
GB201807082D0 (en) | Concept 32 |